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Kinetic instabilityNAD(P)Hquinone oxidoreductase 1 is involved in antioxidant defence and protection from cancer, stabilizing the
apoptosis regulator p53 towards degradation. Here, we studied the enzymological, biochemical and biophysical
properties of two cancer-associated variants (p.R139W and p.P187S). Both variants (especially p.187S) have
lower thermal stability and greater susceptibility to proteolysis compared to the wild-type. p.P187S also has re-
duced activity due to a lower binding afﬁnity for the FAD cofactor as assessed by activity measurements and di-
rect titrations. Native gel electrophoresis and dynamic light scattering also suggest that p.P187S has a higher
tendency to populate unfolded states under native conditions. Detailed thermal stability studies showed that
all variants irreversibly denature causing dimer dissociation, while addition of FAD restores the stability of the
polymorphic forms to wild-type levels. The kinetic destabilization induced by polymorphisms as well as the ki-
netic protection exerted by FAD was conﬁrmed by measuring denaturation kinetics at temperatures close to
physiological. Our data suggest that the main molecular mechanisms associated with these cancer-related vari-
ants are their low binding afﬁnity for FAD and/or kinetic instability. Thus, pharmacological chaperones may be
useful in the treatment of patients bearing these polymorphisms.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
NAD(P)H quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC
1.6.5.2) is a mammalian enzyme which catalyses the two electron
reduction of quinones and related substrates. The enzyme belongs to a
family which also contains mammalian dihydronicotinamide riboside
(NRH) quinone oxidoreductase 2 (NQO2, EC 1.10.99.2) and bacterial
enzymes such asMdaB [1–3]. The family members are typically dimeric
and have an FAD cofactor bound to each subunit [4–7]. They catalyse the
reduction of quinones (and related compounds) through a substituted
enzyme (“ping-pong”) mechanism in which NAD(P)H (or NRH in the
case of NQO2) enters the active site, reduces the FAD and exits as the
oxidised form. The second substrate then enters the active site and is re-
duced by the FADH2 [1,8,9]., circular dichroism; EDC,N-(3-
ride; DSC, differential scanning
othermal titration calorimetry;
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temperature
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@qub.ac.uk (D.J. Timson).There appear to be several physiological roles for NQO1. Its enzymat-
ic function has a minor role in vitamin K metabolism [10,11]. More
generally, the enzyme catalyses the two electron reduction of quinone
substrates, helpingmaintain the vitamin E derivativeα-tocopherol qui-
none and ubiquinone (coenzyme Q) in their reduced, antioxidant forms
[12,13]. The two electron reduction mechanism avoids the production
of semiquinones [14]. These compounds are highly reactive and can in-
duce the production of reactive oxygen species in the cell. However, the
protein also has non-catalytic roles. In its reduced state, it binds to the
apoptosis regulating protein p53 and stabilizes it [15,16]. It also binds
to the tumour suppressor protein p73 and the polyamine biosynthesis
pathway enzyme ornithine decarboxylase [17,18]. NQO1 interacts
with the 20S proteasome reducing its activity, preventing it from
degrading these proteins; however, partially unfolded forms of NQO1
can be efﬁciently degraded by the 20S proteasome [19].
NQO1 is implicated in the molecular pathology of some cancers.
The amount of the enzyme is increased in some colon, liver, breast
and lung tumours [20]. Consequently it has attracted interest as a possi-
ble target for cancer chemotherapy [21–24]. There are also some anti-
cancer pro-drugs (e.g. mitomycin C (MMC) and a MMC analogue,
EO9) which are reduced by NQO1 to the active form [25–27]. Interest-
ingly there are two polymorphic forms of NQO1 which are associated
with higher cancer risks. The ﬁrst one to be characterized, rs1800566
(c.C609T), is sometimes known as the NQO1*2 allele [28,29]. Globally
R139
P187
R139
P187
Fig. 1. Structure of human NQO1 showing the location of Arg139 and Pro187. One mono-
merof theNQO1dimer is shown in green,with the FAD cofactor in yellowand the two res-
idues in green; the other monomer is shown in grey. In both orientations depicted, the
active site lies above the FAD molecule. The lower image shows the protein rotated 90°
around the y-axis relative to the upper one. The ﬁgure was constructed using data from
PDB ID 2F1O [5] and PyMol (www.pymol.org).
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28%, rising to 51% in Han Chinese people (http://www.ensembl.org/
Homo_sapiens/Variation/Population?db=core;r=16:69744645–
69745645;v=rs1800566;vdb=variation;vf=1369178) [30]. It results
in a proline to serine substitution at position 187 in the polypeptide
sequence. Biochemically it is associated with reduced cellular NQO1
protein levels [29]. Cells homozygous for this polymorphismhave unde-
tectable levels of NQO1 activity [29,31]. The reduction in activity also
means that reductive activation of drugs such as MMC is less efﬁcient
and so cells expressing this variant form of NQO1 are less responsive
to these compounds [28]. The p.P187S variant is highly susceptible to
degradation by the 20S proteasome [19,32]. A large number of epidemi-
ological studies have demonstrated that this allele is associatedwith in-
creased cancer risks, although some question its signiﬁcance — for
recent examples, see [33–38]. Smokers who are homozygous for this
mutation have an even greater risk of lung cancer than those who
have at least onewild-type allele [39,40]. Homozygotes also have an in-
creased susceptibility to benzene toxicity [41–43].
A second allele, NQO1*3 (rs1131341, c.C465T), is less well studied
[44,45]. It results in an arginine to tryptophan substitution at position
139. The global frequency of this allele is estimated to 2% with the
highest known frequency (7%) in the Spanish Iberian population
(http://www.ensembl.org/Homo_sapiens/Variation/Population?db=
core;r=16:69748369–69749369;v=rs1131341;vdb=variation;vf=
888801) [30]. p.R139Whas also been associatedwith cancer, speciﬁcal-
ly childhood acute lymphoblastic leukaemia [46,47]. Reduced respon-
siveness to MMC has also been reported [44,45]. Arginine 139 is
positioned within the large catalytic domain on the periphery of the
enzyme; it is in a loop and is solvent exposed. Proline 187 is also posi-
tioned in a loop within the large catalytic domain and although more
buried that arginine 139, is still solvent accessible. Neither residue
forms part of the enzyme's active site (Fig. 1).
To better understand the fundamental molecular pathology of these
two alleles, we expressed and puriﬁed the corresponding recombinant
proteins, providing unprecedented detail on the effects of p.P187S and
characterizing for the ﬁrst time the effects of p.R139W at the molecular
level. This enabled us to propose that their reduced enzymatic activity
results from protein instability (relative to the wild-type) and to inves-
tigate the role of FAD-mediated stabilization of NQO1. Our studies also
provide a framework for the design of therapies aimed to rescue
NQO1 functionality in patients bearing these polymorphisms.
2. Materials and methods
2.1. Expression and puriﬁcation of wild-type and variant NQO1
Hexahistidine-tagged human NQO1 was expressed in, and puriﬁed
from, Escherichia coli cells. The coding sequence for human NQO1 was
ampliﬁed from I.M.A.G.E. clone 3349257 [48] and inserted into the
E. coli expression vector pET46 Ek/LIC (Merck, Nottingham, UK). Site-
directed mutagenesis was carried out using the QuikChange method
[49]. All coding sequences were veriﬁed by DNA sequencing (GATC
Biotech, London, UK). Competent E. coli HMS174 (DE3) cells were
transformed with the appropriate plasmid; a single colony resulting
from this transformation was selected and grown shaking (200 rpm)
at 37 °C overnight in 5 ml of LB supplemented with ampicillin
(100 μg ml−1). This culture was diluted into 1 l of LB supplemented
with ampicillin (100 μg ml−1) and grown until mid-log phase (~4 h).
The culture was induced by the addition of IPTG (1.7 mM) and grown
for a further 3–4 h. The culture was centrifuged at 4200 g at 4 °C for
15 min, the pellets were resuspended in cold buffer R (50 mM Hepes–
NaOH, pH 7.5, 150 mM NaCl, 10%(v/v) glycerol) and stored, frozen,
at −80 °C. Cells were thawed and disrupted by sonication on ice
(3 × 30 s pulses at 100 W with 30 s intervals). Insoluble material was
removed by centrifugation (27,000 g, 20 min at 4 °C). The supernatant
was applied to a nickel agarose resin column (1 ml, His-Select™ Ni2+afﬁnity gel, Sigma-Aldrich) which had been pre-equilibrated with buff-
er A (buffer R, except 500 mM NaCl) and was allowed to pass through
under gravity. The column was washed with 50 ml of buffer A and the
protein was eluted from the column by administration of two 2 ml
volumes of buffer A supplemented with 250 mM imidazole. Fractions
containing NQO1 were identiﬁed by SDS PAGE and were dialysed over-
night against 1 l of buffer R supplemented with 1 mM DTT at 4 °C. The
protein concentration was determined by the method of Bradford [50]
and aliquots (50–100 μl) were stored at−80 °C. At least four indepen-
dent puriﬁcations were performed for each of the NQO1 variants, and
several control experimentswere carried out to conﬁrm that key results
are batch-independent. The dimeric nature of NQO1 enzymes was rou-
tinely checked by size-exclusion chromatography on HiLoad 16/60
Superdex 200 column (GE Healthcare).
For spectroscopic and calorimetric studies, protein concentration
was measured using extinction coefﬁcients based on the primary
sequences (wild-type and p.P187S, ε280 nm = 47,900 M−1 · cm−1;
p.R139W, ε280 nm = 53,400 M−1 · cm−1). Spectra of wild-type and
R139W were corrected for the absorbance of FAD bound during
puriﬁcation (using ε280 nm = 22,000 M−1 · cm−1 and ε450 nm =
11,300 M−1 · cm−1 for free FAD). FAD was removed from NQO1 vari-
ants by performing dilution/concentration cycles in 2 M KBr, 50 mM
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spectra were not corrected due to the FAD bound. The samples were
considered to be FAD free when the A280/A450 N 200, buffer exchanged
to 50 mMHepes–KOH pH 7.4 and stored at−80 °C. FADwas dissolved
in 50mMHEPES–KOHpH7.4 and its concentrationwasmeasured using
ε450 nm = 11,300 M−1 · cm−1.2.2. Enzyme kinetics
NQO1 activity was measured in either 50 mM phosphate buffer
pH 7.4 or 50 mM HEPES–NaOH pH 7.33 using NADH or NADPH as the
electron donor and DCPIP (70 μM) as the electron acceptor; lysozyme
(0.9 μM, Sigma) was included as a stabilizing agent. Initial reaction
rates were determined from changes in A600 nm resulting from the re-
duction of DCPIP and correcting for the non-enzymatic rate of DCPIP re-
duction. All reactions were carried out in triplicate in a reaction volume
of 150 μl in 96-well plates at 37 °C in aMultiskan Spectrum plate reader
(Thermo Scientiﬁc). Enzyme concentration was kept low enough to
provide reliable estimations of changes in A600 nm. To determine the ef-
fect of FAD on the rate of reaction catalysed by the p.P187S variant, ali-
quots of the protein (400 nM) were mixed with FAD (1–64 μM) and
incubated on ice for ~5 min. The enzyme was then diluted into the
assay mix so that the ﬁnal concentration of protein was 4 nM and the
FAD concentration ranged from 10 to 640 nM. Control experiments in
the absence of protein were also carried out.
The apparentMichaelis constant (Km,app) and turnover number (kcat,
app) were determined from plots of enzyme-catalysed rate divided by
enzyme concentration against the corresponding [NAD(P)H]. The data
were ﬁtted to Eq. (1) using non-linear curve ﬁtting in GraphPad Prism
6.0 (GraphPad Software Inc., CA, USA).
v= E½  ¼ kcat;app NAD Pð ÞH½ =Km;app þ NAD Pð ÞH½  ð1Þ
where kcat,app is the apparent turnover number; Km,app is the apparent
Michaelis–Menten constant; [E] is the concentration of enzyme dimer.
Control experiments demonstrated that there was a linear relationship
between the rate and the enzyme concentration in the range used in
these experiments (data not shown). Possible cooperative response to
NADH or NADPH concentration was evaluated by analysis using linear-
ized Hill plots.2.3. Tris–glycine native PAGE
Wild type and variant enzymeswere diluted to a ﬁnal concentration
of 3 μM dimer. An equal volume of native gel loading buffer (125 mM
Tris–HCl, pH 8.8; 20% (v/v) glycerol; 1% (w/v) DTT; 0.002% (w/v)
bromophenol blue) was added and the samples were loaded onto a
10% native polyacrylamide gel (stacking gel pH 6.8; resolving gel
pH 8.8) and electrophoresed at 20mA until the dye in the front reached
the end of the gel. Gels were stained with Coomassie Blue.2.4. Crosslinking
Increasing concentrations of the chemical cross-linkers bissulfo-
succinimidyl-suberate (BS3) and N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) were added to a constant con-
centration of NQO1 and variants (5 μM dimer in buffer R) which had
been preincubated for 15min at 37 °C. The reactionwas allowed to pro-
ceed for 30min at 37 °C afterwhich time it was stopped by the addition
of SDS loading buffer (0.122 M Tris (pH 6.8); 4% (w/v) SDS; 19.5% (v/v)
Glycerol; 0.13 M DTT; Bromophenol Blue 0.05% (w/v)). Reactions were
analyzed using SDS PAGE.2.5. Limited proteolysis
Increasing concentrations of trypsin were added to samples of each
NQO1 variant (3.5 μM dimer in buffer R). Proteolysis was allowed to
proceed for 30 min at 37 °C and was stopped by the addition of SDS
Tris–tricine loading buffer (12% SDS (w/v); 6% DTT (w/v); 30% Glycerol;
150mMTris–HCl pH 7; 0.05% Bromophenol Blue (w/v)). Samples were
denatured by heating at 95 °C for 5 min and analyzed on 13% SDS Tris–
tricine gels [51].
2.6. Differential scanning ﬂuorimetry (DSF)
Wild-type NQO1, p.R139W and p.P187S were diluted to 2 μM
(dimer), 2 μM (dimer) and 10 μM (dimer) respectively. The samples
were loaded in triplicate into a Rotor-Gene Q cycler (Qiagen) and the
high resolution melt protocol was selected. Proteins were subjected to
an increase in temperature form 25 °C to 95 °C in 1 K increments (no
gain optimisation selected). The ﬂuorescence of the cofactor, FAD, was
exploited by exciting at 460 nm and measuring emission at 510 nm
[52,53]. The melting temperature (Tm) of each variant was determined
from the ﬁrst derivative of the melting curve.
2.7. Spectroscopic analyses
All spectroscopic analyses were performed in Hepes–KOH 50 mM
pH 7.4 unless otherwise indicated. Circular dichroism (CD) measure-
ments were performed in a Jasco J-710 spectropolarimeter using 1 mm
(Far-UV) or 5 mm (Near-UV/visible) path-length cuvettes. Thermal
and wavelength scans were acquired using 5 (Far-UV, in K-phosphate
50 mM pH 7.4) or 10 μM (Near-UV/visible) NQO1. Thermal scans by
far-UV CD were registered at 222 nm from 10 to 80 °C at a 2 K/min
scan rate, and the apparent Tm values were estimated as the maxima
of the ﬁrst derivative of thermal scans. In some cases, FAD was added
to a ﬁnal concentration up to 0.25 mM. Fluorescence spectra were ac-
quired in a Cary Eclipse spectroﬂuorometer using 3 mm path length cu-
vettes. All spectrawere acquired at 25 °C at a 50–100 nm/min scan rates
and 4–6 scans were registered and averaged. Dynamic light scattering
(DLS) was carried out in a DynaPro MSX instrument (Wyatt) using
1.5 mm path length cuvettes and 5–10 μM protein (monomer). Fifty
spectrawere acquired for eachDLS analysis, averaged andused to deter-
mine the hydrodynamic radius (assuming a spherical particle shape)
and polydispersity using the average autocorrelation function.
To monitor isothermal denaturation of NQO1 variants, 230 μl of
50 mMHepes–KOH pH 7.4 in the presence of 0–250 μM FAD was incu-
bated at 37 °C or 42 °C for 10 min and then 20 μl of NQO1 enzymes
(~90 μMmonomer) incubatedwith0–250 μMFADwas added andman-
ually mixed (dead time between 10 and 60 s). The ellipticity at 222 nm
was registered as a function of time for up to 50 h. To determine the ap-
parent half-life for denaturation, kinetic traces were analyzed using a
single exponential function.
2.8. Differential scanning calorimetry (DSC)
DSC studies were performed on a capillary VP-DSC differential scan-
ning calorimeter (MicroCal, GE Healthcare) with a cell volume of
0.135 ml. Scans were performed at a 1–3 K/min in a temperature
range of 5–80 °C using 5–30 μM NQO1 (monomer) in 50 mM HEPES–
KOH, pH 7.4. In some experiments, FAD was added to a ﬁnal concentra-
tion up to 0.5 mM.
Thermal denaturation of NQO1 variants was analyzed using a phe-
nomenological two-state irreversible denaturation model with non-
ﬁrst order kinetics [54–56], depicted by (Scheme 1):
Nμ→
k
F
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different number of FAD molecules bound/dimer), F an irreversibly ag-
gregated state that cannot fold back, k is the rate constant for its conver-
sion and 1/μ is the reaction order. Additional details on the analysis of
DSC data can be found in the Supplementary Information.2.9. Isothermal titration calorimetry (ITC)
Experiments were performed in a VP ITC200 microcalorimeter (GE
Healthcare) with a cell volume of 0.206 ml. Cell samples contained
5–6 μM NQO1 variants (dimer) in Hepes–KOH 50 mM pH 7.4 and
were titrated using 0.25 mM FAD by performing 30–50 injections of
0.8–1.2 μl each 180–240 s. Data were corrected for heats of dilution by
performing FAD titrations into buffer. After peak integration, binding
isotherms were ﬁtted using a sequential binding model with two bind-
ing sites or a one identical and independent type of sites model using
the software provided by the manufacturer. Additional details on the
analysis of ITC data can be found in the Supplementary Information.3. Results
3.1. Expression, puriﬁcation and dimerisation of wild-type and variant
NQO1
Wild type human NQO1 could be expressed in, and puriﬁed from,
E. coli with a typical yield of 5 mg per litre of culture. The variants
p.R139W and p.P187S could also be expressed and puriﬁed albeit with
slightly lower yields of 3 and 2 mg per litre of culture respectively
(Supplementary Fig. S1a). Solutions of puriﬁed wild-type and p.R139W
proteins were an intense yellow colour whereas p.P187S was not; this
indicated that p.P187S had substantially less FAD bound. As expected,
homodimers of the wild-type protein were detected by protein–protein
crosslinkingwith both EDC and BS3 and size-exclusion chromatography.
Both variants also formed homodimers (Supplementary Fig. S1b,c,d).
FAD (0–80 μM)hadno effect on the amount of BS3 crosslinking observed
(data not shown).Fig. 2. Steady state enzyme kinetics for wild-type NQO1 and p.R139W. The dependence of rate o
measured at 37 °C with 70 μMDCPIP and 3 nM (dimer) wild-type NQO1 and p.R139W for NAD
enzyme for NADPH (400–550 μM). Each point represents the mean of three separate determin3.2. Activity of wild-type and variant NQO1
Wild-type NQO1 and p.R139W were active with both NADH and
NADPH as electron donors and DCPIP as the electron acceptor (Fig. 2;
Table 1); p.P187S had no detectable activity under these conditions
(data not shown). Pre-incubation of the enzyme with excess FAD prior
to its addition to the reaction recovered the activity of p.P187S (Supple-
mentary Fig. S2) and increased the activity of wild-type and p.R139W
(data not shown). The kinetic constants for wild-type NQO1 and
p.R139W are broadly similar; however, p.R139W is slightly more active
with NADH than the wild-type as judged by the speciﬁcity constant
(kcat/Km; note that this parameter is not dependent on concentration
of ﬁxed substrate in the substituted enzyme mechanism [57]). It has
been reported previously that rat NQO1 exhibits negative cooperativity
towards inhibitorswhich are competitivewith respect to NAD(P)H [58].
Neither wild-type human NQO1 nor p.R139W exhibited cooperativity
towards either NADH or NADPH (Supplementary Fig. S3; Table 1).
3.3. Protein conformation and FAD binding
As isolated, wild-type and p.R139W display similar hydrodynamic
radii (3.60±0.05 and 3.66±0.15 nm, respectively). The hydrodynamic
radius of p.P187S is slightly larger (4.06 ± 0.07 nm, p b 0.01 using a
t-test vs. WT or p.R139W), suggesting that the ensemble average con-
formation of P187S is slightly expanded (Fig. 3A,B) possibly due to the
presence of low levels of partially unfolded states. All three enzymes
behave as monodisperse particles, with polydispersities in the range
of ~10–15% (Fig. 3B). Interestingly, addition of FAD seems to slightly re-
duce the hydrodynamic size of p.P187S while having no signiﬁcant ef-
fect on wild-type and p.R139W (Fig. 3A). Consistent with these effects
on the overall conformation of p.R139W and p.P187S, the far-UV CD
spectra in the absence or presence of 50 μM FAD revealed very similar
secondary structure content in the three NQO1 variants (Fig. 3C). The
tryptophan emission spectra of wild-type and p.R139W show the
same maxima (λmax = 352 nm) and the higher intensity of p.R139W
can be easily explained by the extra tryptophan residue (wild-type
NQO1 has six tryptophans), while the spectra of P187S have a λmax of
348 nm and a higher ﬂuorescence intensity, suggesting some changesn NADH and NADPH concentrations for wild-type NQO1 (top) and R139W (bottom) rates
H and 1.5 nM (dimer) wild-type NQO1 and p.R139W for NADPH (0–350 μM) and 1.0 nM
ations and the error bars are the standard errors of these means.
Table 1
Steady-state kinetic parameters for wild-type NQO1 and p.R139W.
Wild-type NQO1 p.R139W NQO1
NADH NADPH NADH NADPH
Km,app/μM 240 ± 34 154 ± 38 256 ± 48 138 ± 24
kcat,app/s−1 186 ± 12⁎ 732 ± 68 356 ± 31⁎ 598 ± 37
kcat/Km/μM−1 s−1 0.8 ± 0.2⁎ 4.8 ± 1.6 1.4 ± 0.4⁎ 4.3 ± 1.0
h 1.05 ± 0.05 1.10 ± 0.10 1.11 ± 0.04 1.14 ± 0.12
Ratesmeasured at 37 °Cwith varying concentrations of electron donor (NADH or NADPH)
and a constant concentration of electron acceptor, (DCPIP, 70 μM) background rates for
the non-enzymatic reduction of DCPIP at each concentration of electron donor subtracted
to give the enzyme catalysed rate. Values were derived from non-linear curve ﬁtting of
triplicate data. Values marked ⁎ are signiﬁcantly different (p b 0.05; F-test) between the
wild-type and p.R139W.
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quenching by the bound FAD molecules in this variant (Fig. 3D). In
the course of the puriﬁcations, we noticed the faint yellow colour of
p.P187S in contrast to the wild-type and p.R139W. Indeed, the absorp-
tion (Fig. 3E) and circular dichroism spectra (Fig. 3F) in theNear-UVvis-
ible region reveal signals corresponding to FAD bound (withmaxima at
~370 and ~450 nm) in thewild-type and p.R139W,while in the spectra
for P187S these signals are approximately 10-fold weaker (Fig. 3E,F).
To further characterize the binding of FAD toNQO1,we used isother-
mal titration calorimetry (ITC). FAD binding to apo-wild-type and
p.R139W showed complex behaviour, which was not consistent with
the presence of one type of identical and independent sites. Analyses
of the isotherms using a sequential binding model with two binding
sites provide excellent descriptions for FAD binding to wild-type andFig. 3. Conformational properties and FAD binding to NQO1 enzymes. (A) Representative proﬁle
and presence of 250 μM FAD; (B) Values of polydispersity and hydrodynamic radius as function
spectra at 5 μM protein monomer in the absence (solid lines) and presence of 50 μM FAD (da
(E) and CD (F) Near-UV/visible spectra without adding extra FAD (FAD must not be added b
(black), p.R139W (red) and p.P187S (blue). In panels C–F, data are from single measurementsp.R139W enzymes (Fig. 4A). These analyses showed that K1 far exceeds
K2 (20–60 fold), which is consistent with the presence of two indepen-
dent and different types of sites or two identical and interacting types of
sites displaying negative cooperativity (Table 2 and Supplemental infor-
mation). In contrast, FAD binding to apo-p.P187S was well described by
single type of independent and identical site (Fig. 4A), as shown by very
good ﬁts obtained to this model and the fact that K1≈ 4 · K2 in the se-
quential binding model (as expected for identical and independent
sites, see Supplementary Material) (Table 2). This variant displayed be-
tween 10–1000 fold lower binding afﬁnity thanwild-type and p.R139W
(Table 2). This lower afﬁnity in p.P187S explains why the FAD bound to
this variant ismuch lower in the recombinant protein as puriﬁed.More-
over, simulations of FAD binding as a function of its concentration
showed that at physiological free FAD concentrations (58 nM [59]),
the low afﬁnity of p.P187S for FAD will result in a signiﬁcant amount
of apo-protein, which may be unstable intracellularly (Fig. 4B,C,D).
3.4. The cancer-associated variants are unstable compared to the wild-type
A common cause of loss of activity in disease-associated variants of
proteins is reduced structural stability compared to thewild-type. In na-
tive gel electrophoresis, p.R139W ran further than wild-type NQO1,
most likely because of the change in isoelectric point resulting from al-
tering a positively charged arginine residue to uncharged tryptophan
[45]. p.P187S ran as a smear on the native gel in comparison to the
more discrete bands observed for wild-type and p.R139W (Fig. 5A).
These results suggest that p.P187S is more prone to populate partially
unfolded states consistent with our DLS analyses (Fig. 3A,B) and other
previous results [19].s of intensity vs. hydrodynamic radius forwild-type and p.P187S in the absence (solid line)
of added FAD; data are mean± s.d. from three independent experiments; (C) Far-UV CD
shed lines); D) Trp ﬂuorescence emission spectra (λexc = 295 nm); E and F) Absorption
ecause it may give a signal also as free FAD). In all panels, the colour code is wild-type
.
Fig. 4. Titration of NQO1 variants with FAD and ligand binding analyses by a binding polynomial formalism. (A) Binding isotherms of NQO1 enzymes (5–6 μM in dimer) titratedwith FAD.
Lines are best-ﬁts to a sequential bindingmechanism(wild-type and p.R139W) and a one independent and identical type of sites (p.P187S). Data are representative from two independent
titrations. (B and C) Dependence of the mole fraction for different ligation species (solid line: α0, dimer with no FAD bound; dashed line: α1, dimer with 1 FAD bound; dotted line, α2,
dimer with 2 FAD bound) for wild-type (black lines) and p.P187S (blue lines) on free (B) and total (C) FAD concentrations for 1 μMNQO1 dimer. (D) Dependence of the binding capacity
(number of FADmolecules boundperNQO1dimer)on the total FAD concentration for 0.1 (solid lines), 1 (dashed lines) and 10 (dotted lines) μMNQO1dimers. Black lines are forwild-type
and blue lines for p.P187S.
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enzyme as determined by DSF were 50.6 ± 0.2 °C, 49.3 ± 0.2 °C and
43.3 ± 0.9 °C for 2 μM wild-type dimer, 2 μM p.R139W dimer (2 μM
dimer) and 10 μMp.P187S dimer respectively (means of three indepen-
dent determinations ± standard deviation; Fig. 5B). The Tm values for
wild-typeNQO1 andp.R139Wcan be compareddirectly since their con-
centrations were equal; there was a slight, but signiﬁcant, thermal de-
stabilization of the enzyme (p = 0.0007; t-test). It was not possible to
measure the melting temperature of p.P187S at a concentration of
2 μM protein, presumably due to the low level of bound FAD which
gives rise to the ﬂuorescence signal in the assay. p.P187S showed a con-
centration dependent melting temperature: at 20 μM (dimer) it had a
Tm of 47.6±0.3 °C and at 10 μMthe Tmwas 43.3±0.9 °C. This suggests
that if it was possible tomeasure amelting temperature at 2 μMprotein,
it would be even lower than that recorded at 10 μM. Thus, this protein is,Table 2
Thermodynamic parameters for the binding of FAD to NQO1 variants. Data are the mean from
Sequential binding (two sites)
K1 (M−1) ΔH1 (kcal · mol−1) ΔS1 (cal · mol−1 · K−
Wild-type ~1.1 · 109 −19.2 −23.1
p.R139W ~3 · 108 −16.4 −16.5
p.P187S 5.5 · 106 −18.0 −29.4
Identical, independent type of sites
N K (M−1)
p.P187S 2.0 2.1 · 106by far, the most thermally unstable of the three studied here. Suscepti-
bility to limited proteolysis by trypsin increased in the order wild-type
NQO1, p.R139W and p.P187S (Fig. 5C). This mirrors the pattern ob-
served in the enzymes' melting temperatures.
3.5. Thermal stability and FAD binding
Thermal stability of NQO1was studied in depth by differential scan-
ning calorimetry (Fig. 6) and far-UV CD spectroscopy (Supplementary
Fig. S4). By both techniques, we observed a single thermal transition,
with the polymorphisms reducing Tm values by ~2 K (p.R139W) and
~8 K (p.P187S) (Fig. 6A, Supplementary Fig. S4; Table 3). The decrease
in thermal stability by p.P187S agreed well with previous thermal
inactivation assays [19] and our DSF experiments (Fig. 5B). Thermal
denaturation of NQO1 variants was irreversible (Fig. 6B), and scan ratetwo independent titrations.
1) K2 (M−1) ΔH1 (kcal · mol−1) ΔS1 (cal · mol−1 · K−1)
1.7 · 107 −25.5 −52.4
1.4 · 107 −23.7 −46.7
1.1 · 106 −16.0 −21.2
ΔH (kcal · mol−1) ΔS (cal · mol−1 · K−1)
−17.3 −29.0
Fig. 5. Stability of NQO1 variants. (A) Tris–glycine native PAGE: 3 μMdimer of each protein was electrophoresed on a 10% gel at pH 8.8. (B) Differential scanning ﬂuorimetry: thermal melt
comparison for wild-type NQO1, p.R139W and p.P187S triplicate samples of wild-type NQO1 (2 μM dimer), p.R139W (2 μM dimer) and p.P187S (10 μM dimer) in HEPES–OH, pH 7.33
were subjected to an increase in temperature from 25 °C to 95 °C in 1 K increments with excitation at 460 nm and emission measured at 510 nm throughout thereby exploiting the
ﬂuorescence of the cofactor, FAD. Upper panel: the ﬂuorescence emitted throughout the experiment; Lower panel: the ﬁrst derivative of this ﬂuorescence emission graph plotted against
temperature. (C) Limited proteolysis by trypsin. Protein samples (3.5 μMdimer) with increasing concentrations of trypsin: 0, 9, 36, 63, 90, 360, 630, and 900 nM. Trypsinwas dissolved in
buffer R supplemented with 2 mM CaCl2. Results are representative of three independent experiments.
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their denaturation is kinetically-controlled and is likely to involve disso-
ciation of native NQO1 dimers prior to the rate-limiting denaturation
step [54–56]. Despite the heterogeneousmixture of species in the native
state ensemble (with different degrees of saturation of theNQO1dimers
with FAD), we tentatively analyzed the DSC proﬁles using the simplest
model that may account for their behaviour, a two-state irreversible
model with non-ﬁrst order kinetics (Scheme 1). This model reproduced
the experimental DSC scans well (Fig. 6A), yielding consistent parame-
ters for thermal denaturation (Ea and ΔH values), and thus, it seems to
be a reasonable description of the thermal denaturation of NQO1
(Table 3). Moreover, the model includes μ as a ﬁtting parameter
(where 1/μ is the reaction order), which allows the estimation of
the reaction order from the shape of thermal scan [56]: when it is
close to 1, the process is protein concentration independent (i.e.
ﬁrst-order), while a value close to 2means that the process is protein
concentration dependent and involves dissociation of NQO1 dimers
prior to the rate-limiting denaturation step. Indeed, we obtain values
of μ very close to 2 for wild-type and p.R139W, and somewhat lowerfor p.P187S, indicating dimer dissociation upon thermal denatur-
ation for all three variants.
We then obtained NQO1 variants in their apo-form and studied their
stability by DSC. Removal of FAD bound has little effect on the Tm values
(Table 2). The model used to describe thermal denaturation of NQO1
enzymes as puriﬁed also seems to be applicable to the apo-forms
(Table 3). An interesting result found is that apo-NQO1 wild-type and
p.R139W enthalpy changes are much lower than those found for these
variants as puriﬁed. The Tm dependence of ΔH values shows a linear
dependence of 3.9 ± 0.5 kcal · mol−1 · K−1, which is very close to
the theoretical value for a protein of this size (3.8 kcal · mol−1 · K−1)
based on [60] (Fig. 6G). This result has two implications: ﬁrst all apo-
forms are expected to be natively folded (even though p.P187S seems
to be more prone to form partially unfolded states, see [19] and
Figs. 3A, 5A,C); second the higher ΔH values for wild-type and p.R139W
as puriﬁed may arise from the dissociation of FAD, which shows binding
enthalpies of 20–25 kcal · mol−1 (Table 2).
We also investigated the possible effect of FAD on the thermal stabil-
ity of NQO1 variants (Fig. 6E,F; Supplementary Fig. S4B). Addition of
Fig. 6. DSC proﬁles of NQO1 variants. (A) DSC scan at 2 K/min and 10 μM monomer NQO1. Lines are best-ﬁts to a two-state irreversible model with non-ﬁrst order kinetics.
(B) Irreversibility of thermal denaturation. The solid lines are scans up to 80 °C, dashed lines ﬁrst-scans to a temperature close to the completion of the transition, and dotted lines are
second-scans upon cooling down to 5 °C. Performed at 3 K/min and 5 μM monomer NQO1. (C) Scan rate dependence of the Tm values. Performed at 10 μM monomer NQO1.
(D) Protein concentration dependence of Tm values. Performed at 3 K/min. (E) DSC proﬁles of p.P187S in the presence of different FAD concentrations. Lines are best-ﬁts to a two-state
irreversible model with non-ﬁrst order kinetics. Performed at 3 K/min and 10 μMmonomer NQO1. (F) Dependence of the Tm values on FAD concentration. Performed at 3 K/min and
10 μMmonomer NQO1. (G) Denaturation enthalpies of NQO1 enzymes and structure–energetic correlations. Values from single scans are shown as small symbols, while large symbols
are the mean ± s.d. Closed circles are for NQO1 enzymes as puriﬁed, and open triangles for apo NQO1 enzymes (panels c, d, g). The blue line is the linear ﬁt of the data for apo-
proteins providing a slope (ΔCp) of 3.9 ± 0.5 kcal · mol−1 which agrees excellently with the theoretical value of 3.8 kcal · mol−1 from the parameterization of [60] for a folded protein
of this size based on the number of residues. Note that the enthalpy values for NQO1WT and p.R139W are ~40 kcal · mol−1 higher than those found for their apo-NQO1 forms, probably
due to the contribution of FAD release upon denaturation. In panels C, D, F and G, the values displayed for single experiments are best-ﬁt values to the two-state kinetic model (equations
1–3 in Supplementary data) and ﬁtting errors are b0.1 °C (for Tm values) and b3 kcal · mol−1 (for ΔH values).
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pendentmanner; this was somewhat stronger for p.P187S. This result is
not unexpected, since the p.P187S has the lowest occupancy of FAD
binding sites in the absence of added FAD (Fig. 3E,F and [19]) and also
lower afﬁnity for this ligand [1] (Table 2). Since thermal denaturation
of NQO1 is kinetically controlled, these results support the hypothesis
that FAD kinetically stabilizes theNQO1dimers thus increasing their de-
naturation half-lives, which is consistent with FAD binding at the dimer
interface (Fig. 1; [5,61]).3.6. Quantitative estimation of changes in kinetic stability by
polymorphisms and FAD binding
To address, directly, the effect of polymorphisms on the kinetic
stability of NQO1 as well as the stabilizing effect of FAD on them,
we performed isothermal kinetic denaturation studies by Far-UV
CD spectroscopy (Fig. 7). To compare the three variants, we chose
37 °C and 42 °C because they allow determination of kinetic stabil-
ity in a time window of several minutes to hours, and the results
Table 3
Energetic parameters for thermal denaturation of NQO1 enzymes.
NQO1
variant
Tm (°C)a ΔH
(kcal · mol−1)b,c
Ea
(kcal · mol−1)b
μb,c
Wild-type 52.51 ± 0.06 100.1 ± 6.0 44.3 ± 5.8 2.6 ± 0.5
(apo) (51.87 ± 0.03) (64.5 ± 5.6) (67.2 ± 9.6) (1.9 ± 0.4)
p.R139W 50.39 ± 0.04 99.4 ± 5.6 48.9 ± 5.5 2.0 ± 0.3
(apo) (50.07 ± 0.02) (52.7 ± 6.3) (80.7 ± 4.2) (1.5 ± 0.1)
p.P178S 43.83 ± 0.02 32.7 ± 2.2 82.8 ± 4.5 1.4 ± 0.1
(apo) (44.55 ± 0.02) (30.9 ± 6.2) (94.6 ± 6.2) (1.2 ± 0.1)
a At 3 K/min and 10 μM in monomer. Data are from single experiments and errors are
from ﬁttings to a two-state kinetic model (equations 1–3 in Supplementary text).
b Mean ± s.d. from six ﬁve different experiments at different scan rates (1–3 K/min)
and protein concentrations (5–30 μM in monomer).
c Expressed per NQO1 monomer.
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half-lives were estimated at 3.5 μM monomer by ﬁtting to a single
exponential function. In the absence of added FAD, the kinetic sta-
bility of NQO1 is reduced by ~7-fold and ~70-fold in p.R139W and
p.P187S respectively at both 37 °C and 42 °C (Fig. 7A,B). At 37 °C
the half-life for denaturation is 9 min, 1.5 h and 9 h for p.P187S,
p.R139W and wild-type NQO1 (Fig. 7A), while their stability is
about 6-fold lower at 42 °C (Fig. 7B). Addition of FAD increased
the kinetic stability of the variants remarkably (Fig. 7C,D). Indeed,
p.R139W and p.P187S reached the wild-type (as puriﬁed) level of
kinetic stability at concentrations of ~20 and ~250 μM of added
FAD, respectively (Fig. 7D). Overall, our results show that the kinet-
ic stability of p.P187S and p.R139W can be restored in vitro by addi-
tion of micromolar concentrations of FAD.Fig. 7. Kinetic denaturation studies by CD spectroscopy. (A and B) Kinetic traces for denaturati
p.P187S in the presence of different FAD concentrations at 42 °C. In panels A–C, lines are best ﬁ
naturation half-life of p.R139W and p.P187S at 42 °C. For sake of comparison, the denaturatio
dashed line. In panel D, data are best-ﬁt values obtained from single experimental using a sing4. Discussion
Our data demonstrate that both cancer-associated variants are
destabilized compared to the wild-type protein in vitro; p.P187S is sub-
stantially more affected than p.R139W. Kinetic destabilization is over-
come by addition of FAD in a concentration dependent manner, and
this stabilization still increases at concentrations much higher than the
Kd values for FAD, as seen by DSC thermal scan and kinetic denaturation
studies by CD. This behaviour is a consequence of the kinetically con-
trolled nature of NQO1 denaturation. FADmediated stabilization occurs
even at concentrations of ligand at which the enzyme is close to be sat-
urated possibly by reducing the fraction of unligated (no FAD bound)
species kinetically sensitive to denaturation (see [56,62] for a detailed
discussion of these kinetic models). Importantly, our in vitro stability
analyses mirror the intracellular behaviour of p.P187S. In the absence
of an exogenous supply of FAD, this variant is very unstable due to
rapid proteasomal degradation, while addition of FAD (by riboﬂavin
supplementation) increases the resistance towards proteasomal
degradation in a concentration dependent manner [19,32]. There-
fore, the in vitro and the intracellular instabilities of p.P187S are
likely to have a common origin in the low thermodynamic stability
of its apo-form and the low afﬁnity of this variant for FAD. In turn,
increasing FAD saturation may boost p.P187S stability by shifting
the equilibrium towards the holo-form, and also enhance speciﬁc
activity by overcoming the afﬁnity defect of this variant for FAD.
Our results also suggest a similar scenario for p.R139W, although
in this case, we expect a less dramatic decrease in intracellular sta-
bility and a higher speciﬁc activity in the absence of FAD (or riboﬂa-
vin) supplementation.on of NQO1 variants without added FAD at 37 °C (A) and 42 °C (B). (C) Kinetic traces for
ts to a single exponential function. (D) FAD concentration dependence of the apparent de-
n half-life for wild-type at this temperature without added FAD is shown as a horizontal
le exponential function, and ﬁtting errors are lower than 10% of the best-value half life.
2172 A.L. Pey et al. / Biochimica et Biophysica Acta 1842 (2014) 2163–2173Previously, Moscovitz and coworkers were able to detect by mass
spectrometry a population of partially unfolded states in apo-NQO1,
while binding of FAD seems to shift the folding equilibrium towards
the native dimer [19]. Our conformational and kinetic stability studies
further support this study, and demonstrate that similar effects occur
in p.P187S and p.R139W. The data ofMoscovitz et al. show that partially
folded states are populated at low levels in the native state ensemble
(see the low intensities of the partially unfolded vs. folded peaks in
Fig. 2 of [19]), and thus, they do not largely perturb the averagedmolec-
ular properties reported byushere.When corrected for the contribution
of FAD binding, the denaturation enthalpies of all (apo-)NQO1 variants
at their Tm are consistent with a folded native state based on well-
known structure-energetics parameterizations (see Fig. 5G), indicating
that departures from the folded state (i.e. the partially unfolded states
reported by Moscovitz et al. [19]) are marginal. Nevertheless, since
these partially unfolded states may be more prone to aggregation and
degradation than the native state, they may be critical to determine
the kinetic stability in vitro (our work) and in cells [19]. By simply
assuming that FAD binds and selectively stabilizes the native state, the
partially unfolded stateswill be poorly populated in the holo-state, con-
sistent with the results obtained by Moscovitz et al. using mass spec-
trometry [19] and our thermal and kinetic stability studies. Thus, FAD
binding may enhance NQO1 activity by increasing the thermodynamic
stability of the folded dimer under native conditions. Interestingly,
Oliveberg and coworkers have shown that binding of copper and zinc
ions to apo-SOD provides a larger thermodynamic stabilization than
the sum of dimerization and monomer unfolding in the apo-state [63].
Since p.R139W has comparable kinetic constants to wild-type
NQO1, the explanation for its different behaviour in vivo may lie
in its activity towards its natural electron acceptor substrates. Pre-
viously, p.R139W has been shown to have a higher Km value for
DCPIP but the same Km value for menadione; it also has a 60%
lower activity in the reduction of mitomycin C (MMC) [45]. There-
fore, p.R139W may have much higher Km values and/or lower kcat
values for quinone substrates in vivo. Its slightly decreased stability
compared to wild-type NQO1 may also be a factor. This variant may
also be less effective at stabilizing p53; irradiation-induced expres-
sion of p53 has been shown to be attenuated in cells expressing
p.R139W [46]. Interestingly, in the structurally related enzyme
NQO2, reduced oxidoreductase activity resulting from a common
polymorphism (rs1143684; p.F47L) is associated with improved
prognosis in some cancers [64–66]. This suggests that, despite
structural and catalytic similarities between the two enzymes,
their roles in the cell have important differences.
As demonstrated here, the stability and oxidoreductase activity
of p.P187S recover in the presence of excess FAD. Recent studies
on human cells which express this form of NQO1 have shown that
supplementation of the cell growth media with the FAD precursor
riboﬂavin causes stabilization of p.P187S, leading to increased
levels in the cells and increased NQO1 activity [19]. Taken together,
this suggests that dietary supplementation with riboﬂavin-rich
foods may be advisable for individuals with the p.P187S and
p.R139W polymorphisms, especially those who are homozygous.
This therapy resembles those used for different inborn errors of me-
tabolism caused by protein instability, and based on vitamin and/or
cofactor supplementation, some of which involve FAD-dependent
enzymes [67–71]. Furthermore, our results predict that the levels
of vitamin B2 required to rescue p.R139W will be lower than
those required for p.P187S (see Fig. 7). Alternatively a “pharmaco-
logical chaperone” approach could be taken which would require
the identiﬁcation of a small molecule which would speciﬁcally
and kinetically stabilise p.P187S and p.R139W, an approach previ-
ously shown to be successful in conformational metabolic diseases
[68,72,73]. Some of the methods for studying NQO1 stability de-
scribed here, most notably DSF and DSC, may prove valuable in
screening for and characterizing such compounds.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.08.011.
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